Lung Cancer
Conditions
Interventions
Group A:Uniportal robotic assisted surgery in lung cancer
Group B: Uniportal thoracoscopic assisted surgery in lung cancer
Sponsors
The First Affiliated Hospital of Zhengzhou University
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1) Age: 18-75 years old, gender not limited; 2) Surgical resectable non-small cell lung cancer: (Phase I-IIIa, AJCC,9th), If the preoperative stage is IIb-IIIA, according to the International Expert Consensus on Neoadjuvant Immunotherapy for Non Small Cell Lung Cancer, neoadjuvant chemotherapy/neoadjuvant chemotherapy combined with immunotherapy can be used for 2-4 cycles before surgical treatment. The neoadjuvant chemotherapy combined with immunotherapy regimen can be selected as follows: squamous cell carcinoma: docetaxel/albumin paclitaxel/gemcitabine+cisplatin/carboplatin, adenocarcinoma: pemetrexed/vinorelbine/paclitaxel/docetaxel+cisplatin/carboplatin, large cell lung cancer: etoposide+cisplatin/carboplatin; 3) ECOG score: 0-1 points; 4) ASA: Level I-III; 5) The main organ function is normal, which meets the following criteria: (1) Blood routine examination: a.HB>=90g/L; b.ANC>=1.5×10^9/L; c.PLT >=80×109/L; (2) Biochemical examination: a.ALB>=30g/L; b. ALT and AST = 60ml/min; 6). Doppler ultrasound evaluation: Left ventricular ejection fraction (LVEF) >= lower limit of normal (50%); 7). Women of childbearing age should agree to use contraceptive measures (such as intrauterine devices, birth control pills, or condoms) during the study period and within 6 months after the end of the study; Within 7 days prior to enrollment in the study, the serum or urine pregnancy test must be negative and the patient must be non lactating; Men should agree that patients must use contraception during the study period and within 6 months after the end of the study period; 8). The subjects voluntarily joined this study, signed informed consent forms, had good compliance, and cooperated with follow-up.
Exclusion criteria
Exclusion criteria: 1)Pregnant or lactating women; 2)Patients who have had other malignancies within 5 years (except basal cell carcinoma of the skin and carcinoma in situ of the cervix that has been cured); 3) Patients who have a history of psychotropic drug abuse and cannot quit or have mental disorders; 4) Patients who have participated in clinical trials of other drugs within four weeks; 5) History of abdominal surgery; 6) Preoperative planning should be combined with excision of other organs, such as gallbladder, thyroid, liver, etc 7) Severe spinal deformity; 8) Patients with concomitant diseases (such as acute myocardial infarction, cerebral infarction, pulmonary embolism, etc.) that, according to the judgment of the investigator, seriously endanger the safety of the patient or affect the completion of the study; 9) Those deemed unsuitable for inclusion by the researchers.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Perioperative complications;Progression free survival; | — |
Secondary
| Measure | Time frame |
|---|---|
| Overall survival; | — |
Countries
China
Contacts
Public ContactLi Xiangnan
The First Affiliated Hospital of Zhengzhou University
Outcome results
None listed